gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

GINS complex subunit 2

Psf2, pfs2, GINS2
The yeast heterotetrameric GINS complex is made up of Sld5 (GINS4; MIM 610611), Psf1 (GINS1; MIM 610608), Psf2, and Psf3 (GINS3; MIM 610610). The formation of this complex is essential for the initiation of DNA replication in yeast and Xenopus egg extracts (Ueno et al., 2005 [PubMed 16287864]). See GINS1 for additional information about the GINS complex.[supplied by OMIM, Mar 2008] (from NCBI)
Sponsored links
Top mentioned proteins: Psf1, HAD, CAN, SET, AGE
Papers on Psf2
First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study.
Mok et al., Seoul, South Korea. In Jama Oncol, Jan 2016
Secondary end points included PFS2 (time to off-erlotinib progression if erlotinib therapy was extended beyond progression at patient and/or investigator discretion), objective response rate, disease control rate, overall survival, and safety.
Is second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncology.
Gumus et al., İstanbul, Turkey. In Tumour Biol, Dec 2015
According to survival analysis, median progression-free survival after first-line treatment (PFS2) was 3.5 months (standard error (SE) 0.2; 95 % confidence interval (CI), 3.2-3.9),
Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Antonarakis et al., Seattle, United States. In Prostate, Nov 2015
The combined progression-free survival (combined PFS: PFS1 + PFS2) of abiraterone-to-docetaxel is compared to the reverse sequence, where PFS1 and PFS2 represent progression-free survival on the first and second agents respectively.
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.
Boccadoro et al., Bologna, Italy. In J Clin Oncol, Nov 2015
Progression-free survival 2 (PFS2; time from random assignment until the second progression or death) may represent an additional tool to estimate outcome.
Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
Wu et al., Guangzhou, China. In Oncotarget, Oct 2015
Median progression free survival to physician assessment progression (PFS2) and difference between PFS1 and PFS2 (PFS difference) were also recorded.
Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-Distance.
Langecker et al., Mountain View, United States. In Neoplasia, Sep 2015
Hence, in this setting, a new end point, PFS2, is required to measure this field of influence.
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Koopman et al., Amsterdam, Netherlands. In Lancet, Jun 2015
On first progression (defined as PFS1), patients in both groups were to receive the induction regimen of CAPOX-B until second progression (PFS2), which was the study's primary endpoint.
Effects of second and subsequent lines of chemotherapy for metastatic breast cancer.
Ro et al., South Korea. In Clin Breast Cancer, Feb 2015
The median progression-free survival (PFS) was 7.6 months for first-line (PFS1) versus 5.1 months for second-line (PFS2) versus 3.6 months for third-line (PFS3) chemotherapy.
Post progression survival in glioblastoma: where are we?
Brandes et al., Bologna, Italy. In J Neurooncol, 2015
The median PFS following second line chemotherapy (PFS2) was 2.5 months (95 % CI 2.1-2.9) and the rate of patients free of progression at 6 months (PFS2-6 mo), was 21.6 % (95 % CI 16.3-26.9
High GINS2 transcript level predicts poor prognosis and correlates with high histological grade and endocrine therapy resistance through mammary cancer stem cells in breast cancer patients.
Zhu et al., Xi'an, China. In Breast Cancer Res Treat, 2014
GINS2, a subunit of the GINS complex, is overexpressed in lung adenocarcinoma and metastatic breast tumor; however, its prognostic power and possible molecular mechanisms in breast cancer (BC) remain unclear.
Differential protein expression and novel biomarkers related to 5-FU resistance in a 3D colorectal adenocarcinoma model.
Kuh et al., Seoul, South Korea. In Oncol Rep, 2014
Among these, collapsin response mediator protein 2 (CRMP-2), DNA replication complex GINS protein PSF2 (PSF-2) and selenium-binding protein 1 (SBP-1) were notable not only for their differential expression but also for decreased expression following 5-FU exposure, indicating their possible roles as novel biomarkers for sensitivity (CRMP-2, PSF-2) as well as resistance (SBP-1) to 5-FU.
DNA damage enhanced by the attenuation of SLD5 delays cell cycle restoration in normal cells but not in cancer cells.
Takakura et al., Suita, Japan. In Plos One, 2013
SLD5 is a member of the GINS complex composed of PSF1, PSF2, PSF3 and SLD5, playing a critical role in the formation of the DNA replication fork with CDC45 in yeast.
Partner of Sld five 3: a potential prognostic biomarker for colorectal cancer.
Wang et al., Yantai, China. In Diagn Pathol, 2013
BACKGROUND: Partner of Sld five 3 (PSF3) is a member of the evolutionarily conserved heterotetrameric complex "Go-Ichi-Ni-San" (GINS), which consists of SLD5, PSF1, PSF2, and PSF3.
Properties of the human Cdc45/Mcm2-7/GINS helicase complex and its action with DNA polymerase epsilon in rolling circle DNA synthesis.
Hurwitz et al., New York City, United States. In Proc Natl Acad Sci U S A, 2012
Data show that using a 200-nt primed circular DNA substrate, the combined action of DNA polymerase epsilon and the Cdc45/Mcm2-7/GINS (CMG complex) leads to the formation of products >10 kb in length.
RAD51- and MRE11-dependent reassembly of uncoupled CMG helicase complex at collapsed replication forks.
Costanzo et al., London, United Kingdom. In Nat Struct Mol Biol, 2012
Data show that MRE11- and RAD51-dependent fork repair leading to reloading of the GINS onto the MCM-CDC45 complex still engaged with the DNA could be sufficient to restore a functional CDC45-MCM-GINS (CMG) helicase complex.
GINS and Sld3 compete with one another for Mcm2-7 and Cdc45 binding.
Kaplan et al., Nashville, United States. In J Biol Chem, 2011
GINS (Psf1, Psf2, Psf3, and Sld5) and Sld3 compete with one another for Mcm2-7 and Cdc45 binding
Integrative functional genomics analysis of sustained polyploidy phenotypes in breast cancer cells identifies an oncogenic profile for GINS2.
Kallioniemi et al., Turku, Finland. In Neoplasia, 2010
Data suggest that GINS2 to be associated with the aggressive characteristics of a subgroup of breast cancers in vivo.
Inactivation of the pre-mRNA cleavage and polyadenylation factor Pfs2 in fission yeast causes lethal cell cycle defects.
Norbury et al., Oxford, United Kingdom. In Mol Cell Biol, 2005
Pfs2 is required for chromosome segregation and replication, and pre-mRNA cleavage and polyadenylation. [Pfs2]
Presentation of viral antigen by MHC class I molecules is dependent on a putative peptide transporter heterodimer.
DeMars et al., Boston, United States. In Nature, 1992
Immunochemical and genetic data demonstrate that the PSF1 polypeptide is associated with a complementary transporter chain, which is polymorphic and is encoded by the PSF2 gene, which is closely linked to PSF1.
Assembly and function of the two ABC transporter proteins encoded in the human major histocompatibility complex.
Townsend et al., London, United Kingdom. In Nature, 1992
The molecular defect in a new mutant, BM36.1, is shown to be in the ATP-binding domain of the RING11/PSF2 protein.
share on facebooktweetadd +1mail to friends